🔗 Share this article

Given that the United States undertakes sweeping revisions to its vaccination schedules, one figure has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who rose to prominence by questioning coronavirus shots throughout the global health crisis and has zeroed in on potential deaths after COVID-19 immunization in her brief time at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Immunization Schedule

Agency leaders had intended to unveil major revisions to the pediatric vaccination calendar in December, bringing the US with Denmark’s vaccine program, according to reports – a substantial departure that would place the US out of step with much of the global community with little proof for benefit. The announcement has been postponed until the coming year.

In place of the top vaccines chief, Høeg is listed to present at the meeting. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to lead the division this calendar year.

A Shift at the FDA

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and biologics centers as Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a renewed priority upon rolling back long-standing immunizations at the FDA.

The new acting director has frequently advocated for discontinuing some pediatric vaccine recommendations in the US so as to align more similar to Denmark's approach, a society with nationalized medicine and a number of inhabitants about the population of Wisconsin’s.

So far comments, she has continued to focus on vaccines – typically the responsibility of Dr. Prasad, director of the FDA’s CBER – as opposed to pharmaceutical oversight.

Questions Over Qualifications

Dr. Høeg has no obvious experience in pharmaceutical research, regulation or leadership, which has been typical for former heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for leading the drug-regulation department, remarked a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She is not versed in leading a large organization. She lacks background in drug approvals.”

Former commissioners of CBER would “grasp regulatory frameworks and the underlying principles of medication creation”, commented a former acting FDA commissioner. “Objectively, she has not acquired the kind of background that prior appointees who headed CBER have had.”

The drug center has an vast workload at the agency, Woodcock stated.

“Many people just pays attention on the novel medication approvals, but the generic drug division authorizes numerous off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and so forth, and each of these must be looked after,” she said. “The thing you overlook, that’s the thing that I always told people is going to cause problems.”

Additionally, a substantial leadership aspect to the job, which manages in excess of 5,000 employees. “It is a enormous management job, if you perform it correctly,” she said.

Agency Reaction and Controversial Policies

In response to concerns about Dr. Høeg's qualifications and whether this selection represents greater collaboration among regulatory chiefs on immunizations, a representative responded that the “questions are based on flawed assumptions”.

“This background aligns with the functions of her position,” the official explained, citing the period Dr. Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg takes over the agency head's recently launched expedited review system, a disputed one-day medication authorization process that apparently concerned her former heads. “By what process are these medications being picked for this voucher program? Who takes the decisions?” Howard questioned. “There’s a lot of secrecy going on at the agency right now.”

Broadly speaking, he said, “the Food and Drug Administration looks to be trending towards more relaxed oversight of pharmaceuticals, except for shots.”

Public Track Record on Vaccines

Regarding immunizations, Dr. Høeg has a more established, if troubling, past, some experts have noted. She authored a research paper using unverified crowd-sourced reports to estimate the rate of myocarditis following Covid immunization. She advised the Florida top health official Dr. Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccines are pose a greater threat than they are.

Among her “desired changes” for the incoming government encompassed changing regulations for recently developed shots and discontinuing “optional” vaccines, she said after the election on a podcast. At the FDA, Dr. Høeg has allegedly floated the idea of excluding young men from getting COVID-19 vaccinations.

“She’s an complete ideologue who begins with her preconceived notions and reverse-engineers to retrofit the data in a very disingenuous, fraudulent way,” Howard said.

Gaining Influence and a “Campaign of Retribution”

Høeg joined other skeptics, {like|